RU2016107884A - Фармацевтическая композиция для лечения и/или профилактики рака - Google Patents
Фармацевтическая композиция для лечения и/или профилактики рака Download PDFInfo
- Publication number
- RU2016107884A RU2016107884A RU2016107884A RU2016107884A RU2016107884A RU 2016107884 A RU2016107884 A RU 2016107884A RU 2016107884 A RU2016107884 A RU 2016107884A RU 2016107884 A RU2016107884 A RU 2016107884A RU 2016107884 A RU2016107884 A RU 2016107884A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- variable region
- amino acid
- acid sequence
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 201000011510 cancer Diseases 0.000 title claims 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims 6
- 230000002265 prevention Effects 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 4
- 150000001720 carbohydrates Chemical group 0.000 claims 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 2
- 229930182474 N-glycoside Natural products 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940126534 drug product Drugs 0.000 claims 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100029949 Caprin-1 Human genes 0.000 claims 1
- 101710072528 Caprin-1 Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 208000006971 mastocytoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (51)
1. Антитело, которое включает:
вариабельную область тяжелой цепи, включающую определяющие комплементарность области SEQ ID NO: 1, 2 и 3, и
вариабельную область легкой цепи, включающую определяющие комплементарность области SEQ ID NO: 4, 5 и 6, и
обладает иммунологической реактивностью в отношении белка CAPRIN-1, или его фрагмент.
2. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 8, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 15.
3. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 10, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 15.
4. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 7, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 15.
5. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 8, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 13.
6. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 7, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 12.
7. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 8, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 12.
8. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 7, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 13.
9. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 10, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 14.
10. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 8, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 11.
11. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 7, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 11.
12. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 9, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 15.
13. Антитело или его фрагмент по п. 1, в которых:
вариабельная область тяжелой цепи включает аминокислотную последовательность SEQ ID NO: 20, и
вариабельная область легкой цепи включает аминокислотную последовательность SEQ ID NO: 21.
14. Антитело или его фрагмент по любому из пп. 1-13, где антитело является человеческим антителом, гуманизированным антителом, химерным антителом, одноцепочечным антителом или мультиспецифическим антителом.
15. Антитело или его фрагмент по любому из пп. 1-13, где антитело или его фрагмент конъюгированы с противоопухолевым средством.
16. Антитело по любому из пп. 1-15, где антитело включает замену одной или более аминокислот в константной области тяжелой цепи.
17. Антитело по любому из пп. 1-16, где антитело является антителом, не имеющим фукозы, присоединяемой к N-ацетилглюкозамину на восстанавливающем конце углеводной цепи N-гликозид-связанной углеводной цепи, присоединенной к константной области тяжелой цепи.
18. Композиция антител, включающая антитело по п. 17 и антитело по любому из пп. 1-16, имеющее фукозу, присоединенную к N-ацетилглюкозамину на восстанавливающем конце углеводной цепи N-гликозид-связанной углеводной цепи, присоединенной к константной области тяжелой цепи.
19. Клетка, продуцирующая антитело по п. 17 или композицию антител по п. 18.
20. Фармацевтическая композиция для лечения и/или профилактики рака, включающая антитело или его фрагмент по любому из пп. 1-15, антитело по п. 16 или 17, или композицию антител по п. 18 в качестве действующего вещества.
21. Фармацевтическая композиция по п. 20, где рак является раком молочной железы, раком почки, раком поджелудочной железы, раком толстой и прямой кишки, раком легкого, опухолью головного мозга, раком желудка, раком матки, раком яичника, раком предстательной железы, раком мочевого пузыря, раком пищевода, лейкозом, лимфомой, раком печени, раком желчного пузыря, саркомой, мастоцитомой, меланомой, раком коры надпочечников, опухолью Юинга, лимфомой Ходжкина, мезотелиомой, множественной миеломой, раком яичка, раком щитовидной железы или злокачественной опухолью головы и шеи.
22. Комбинированный лекарственный продукт для лечения и/или профилактики рака, включающий фармацевтическую композицию по п. 20 или 21 и фармацевтическую композицию, включающую противоопухолевое средство.
23. ДНК, кодирующая антитело или его фрагмент по любому из пп. 1-16.
24. Способ лечения и/или предотвращения рака, включающий введение субъекту антитела или его фрагмента по любому из пп. 1-16, антитела по п. 17, композиции антител по п. 18, фармацевтической композиции по п. 20 или 21, или комбинированного лекарственного продукта по п. 22.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-166164 | 2013-08-09 | ||
JP2013166164 | 2013-08-09 | ||
PCT/JP2014/071094 WO2015020212A1 (ja) | 2013-08-09 | 2014-08-08 | 癌の治療及び/又は予防用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016107884A true RU2016107884A (ru) | 2017-09-14 |
RU2678138C2 RU2678138C2 (ru) | 2019-01-23 |
Family
ID=52461536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016107884A RU2678138C2 (ru) | 2013-08-09 | 2014-08-08 | Фармацевтическая композиция для лечения и/или профилактики рака |
Country Status (17)
Country | Link |
---|---|
US (1) | US9862774B2 (ru) |
EP (1) | EP3031826B1 (ru) |
JP (1) | JP6447130B2 (ru) |
KR (1) | KR102255616B1 (ru) |
CN (1) | CN105452294B (ru) |
AU (1) | AU2014303375B2 (ru) |
BR (1) | BR112016001753B1 (ru) |
CA (1) | CA2918989C (ru) |
DK (1) | DK3031826T3 (ru) |
ES (1) | ES2704909T3 (ru) |
HU (1) | HUE042081T2 (ru) |
MX (1) | MX360671B (ru) |
PL (1) | PL3031826T3 (ru) |
PT (1) | PT3031826T (ru) |
RU (1) | RU2678138C2 (ru) |
TR (1) | TR201819812T4 (ru) |
WO (1) | WO2015020212A1 (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0911926A2 (pt) * | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
MX2011001445A (es) | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
DK3031826T3 (en) | 2013-08-09 | 2018-12-17 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of cancer |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
CA3041979A1 (en) * | 2016-10-28 | 2018-05-03 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
JP7342701B2 (ja) | 2018-03-30 | 2023-09-12 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
BR112021025034A2 (pt) | 2019-06-13 | 2022-04-26 | Bolt Biotherapeutics Inc | Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado |
US20220347310A1 (en) | 2019-09-30 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
IL292396A (en) | 2019-10-25 | 2022-06-01 | Bolt Biotherapeutics Inc | Thianozapine immunoconjugates and uses thereof |
BR112022018171A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
JPWO2021182574A1 (ru) | 2020-03-12 | 2021-09-16 | ||
KR20220152309A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
KR20220153621A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
CA3175137A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
CA3176626A1 (en) | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
CA3186059A1 (en) | 2020-08-13 | 2022-02-17 | Romas Kudirka | Pyrazoloazepine immunoconjugates, and uses thereof |
BR112023026992A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
JPWO2022270523A1 (ru) | 2021-06-23 | 2022-12-29 | ||
KR20240042415A (ko) | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
WO2023008459A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Ind Inc | Medicamento para el tratamiento y/o prevencion de cancer. |
JPWO2023033129A1 (ru) | 2021-09-03 | 2023-03-09 | ||
WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
WO2024005123A1 (ja) * | 2022-06-30 | 2024-01-04 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
BR9508959A (pt) | 1994-09-19 | 1997-12-30 | Ricardo J Moro | "Detecção e tratamento de cancer" |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
JP3998419B2 (ja) | 1998-04-03 | 2007-10-24 | 中外製薬株式会社 | ヒト組織因子(tf)に対するヒト型化抗体およびヒト型化抗体の作製方法 |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
IL140845A0 (en) | 1998-07-14 | 2002-02-10 | Corixa Corp | Compositions for therapy and diagnosis of prostate cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
AU5285899A (en) | 1998-07-21 | 2000-02-14 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anti hepatitis c virus antibody and uses thereof |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
JP2002540790A (ja) | 1999-04-02 | 2002-12-03 | コリクサ コーポレイション | 肺癌の治療および診断のための化合物ならびにその使用のための方法 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
AU1438001A (en) | 1999-10-29 | 2001-05-14 | Human Genome Sciences, Inc. | 27 human secreted proteins |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
JP2004526401A (ja) | 2000-03-29 | 2004-09-02 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
US7101977B2 (en) | 2001-07-17 | 2006-09-05 | Research Development Foundation | Therapeutic agents comprising pro-apoptotic proteins |
RU2319709C2 (ru) | 2001-07-17 | 2008-03-20 | Рисерч Дивелопмент Фаундейшн | Терапевтические агенты, содержащие проапоптозные белки |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
EP1629119A2 (en) | 2003-04-29 | 2006-03-01 | Wyeth | Methods for diagnosing aml and mds by differential gene expression |
EP2003196A3 (en) | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
DE10359795A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Technology Services Gmbh | Strangverdampfervorrichtung |
JP2008506352A (ja) | 2004-01-26 | 2008-03-06 | デビオビジョン・インコーポレーテッド | 新生物特異的ポリペプチド及びその使用 |
DK1735348T3 (da) | 2004-03-19 | 2012-07-16 | Imclone Llc | Humant anti-epidermalt vækstfaktorreceptorantistof |
SI1730191T1 (sl) | 2004-03-30 | 2011-11-30 | Glaxo Group Ltd | Imunoglobulin-vezavni hOSM |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
RU2297241C2 (ru) | 2004-11-22 | 2007-04-20 | Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития | Химерный белок для лечения злокачественных лимфом |
PL1839662T3 (pl) | 2005-01-19 | 2010-08-31 | Zeria Pharm Co Ltd | Środek przeciwnowotworowy |
KR20130089280A (ko) | 2005-01-21 | 2013-08-09 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
AU2006214105A1 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
MX2007011024A (es) | 2005-03-11 | 2009-11-23 | Vermillion Inc | Biomarcadores para cancer de ovario y cancer de endometrio: hepcidin. |
JP2006318040A (ja) | 2005-05-10 | 2006-11-24 | Ricoh Co Ltd | サービス提供システム、プログラムおよび記録媒体 |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
AU2007205257B2 (en) | 2006-01-05 | 2013-07-25 | The Ohio State University Research Foundation | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
CA2642342A1 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
KR101633351B1 (ko) | 2007-10-25 | 2016-06-27 | 도레이 카부시키가이샤 | 암의 검출 방법 |
JP5663834B2 (ja) * | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
TWI527593B (zh) | 2008-03-18 | 2016-04-01 | 建南德克公司 | 抗her2抗體-藥物結合物及化療劑之組合及使用方法 |
BRPI0911926A2 (pt) | 2008-08-05 | 2020-08-18 | Toray Industries, Inc | composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo. |
DK2324842T3 (da) | 2008-08-05 | 2015-06-22 | Toray Industries | Immunitetsinducerende middel |
MX2011001445A (es) | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
WO2010018883A1 (en) | 2008-08-14 | 2010-02-18 | Myungjoo Kwon | Magnetic-piezoelectric combine sensor using piezoelectric single crystal |
BRPI1015234A2 (pt) | 2009-06-22 | 2018-02-20 | Medimmune Llc | regiões fc projetadas para conjugação sítio específica. |
BR112012003686B1 (pt) | 2009-08-19 | 2021-09-21 | Merck Patent Gmbh | Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo |
US8642292B2 (en) * | 2009-09-22 | 2014-02-04 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
EP2532365B1 (en) * | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
KR101801667B1 (ko) | 2010-02-04 | 2017-11-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
HUE040012T2 (hu) | 2010-02-04 | 2019-02-28 | Toray Industries | Gyógyászati ágens rák kezelésére és/vagy megelõzésére |
MX340017B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
AU2011211682B2 (en) * | 2010-02-04 | 2015-08-13 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
AU2011211699B2 (en) | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
EP2360965A1 (en) | 2010-02-12 | 2011-08-24 | ST-Ericsson SA | Handling of measurements for selecting a cell in a network |
WO2011120134A1 (en) | 2010-03-29 | 2011-10-06 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
KR101271964B1 (ko) | 2010-07-08 | 2013-06-07 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
EA028515B1 (ru) | 2010-07-26 | 2017-11-30 | Ле Лаборатуар Сервье | Способы и композиции для терапии рака печени |
US9181334B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
CA2844030C (en) | 2011-08-04 | 2019-09-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
MX348577B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
AU2012290957B2 (en) | 2011-08-04 | 2017-04-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
MX348578B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
DK2740489T3 (en) | 2011-08-04 | 2017-01-16 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
JP5855969B2 (ja) | 2012-02-15 | 2016-02-09 | 株式会社神戸製鋼所 | 金属板の曲げ加工方法 |
ES2739612T3 (es) | 2012-02-21 | 2020-02-03 | Toray Industries | Composición farmacéutica para el tratamiento de cáncer |
KR102005308B1 (ko) | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
CA2865020C (en) | 2012-02-21 | 2021-01-26 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
DK2818483T3 (en) | 2012-02-21 | 2017-10-23 | Toray Industries | Medical composition for the treatment and / or prevention of cancer |
EP2832368B1 (en) | 2012-03-28 | 2021-11-10 | Hiroshima University | Fibrosis suppression by inhibiting integrin alpha8beta1 function |
JPWO2013147189A1 (ja) | 2012-03-30 | 2015-12-14 | 積水化学工業株式会社 | 蒸着用硬化性樹脂組成物、樹脂保護膜、有機光デバイス、及び、有機光デバイスの製造方法 |
MX357965B (es) | 2012-03-30 | 2018-08-01 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. |
US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
CA2879304C (en) | 2012-07-19 | 2020-07-14 | Toray Industries, Inc. | Method for detecting cancer |
EP2876447B1 (en) | 2012-07-19 | 2019-11-20 | Toray Industries, Inc. | Method for detecting cancer |
DK3031826T3 (en) | 2013-08-09 | 2018-12-17 | Toray Industries | Pharmaceutical composition for the treatment and / or prevention of cancer |
-
2014
- 2014-08-08 DK DK14834828.7T patent/DK3031826T3/en active
- 2014-08-08 PT PT14834828T patent/PT3031826T/pt unknown
- 2014-08-08 AU AU2014303375A patent/AU2014303375B2/en active Active
- 2014-08-08 MX MX2016001640A patent/MX360671B/es active IP Right Grant
- 2014-08-08 EP EP14834828.7A patent/EP3031826B1/en active Active
- 2014-08-08 KR KR1020167004263A patent/KR102255616B1/ko active IP Right Grant
- 2014-08-08 JP JP2014548217A patent/JP6447130B2/ja active Active
- 2014-08-08 US US14/910,878 patent/US9862774B2/en active Active
- 2014-08-08 WO PCT/JP2014/071094 patent/WO2015020212A1/ja active Application Filing
- 2014-08-08 ES ES14834828T patent/ES2704909T3/es active Active
- 2014-08-08 CA CA2918989A patent/CA2918989C/en active Active
- 2014-08-08 PL PL14834828T patent/PL3031826T3/pl unknown
- 2014-08-08 RU RU2016107884A patent/RU2678138C2/ru active
- 2014-08-08 CN CN201480044559.2A patent/CN105452294B/zh active Active
- 2014-08-08 HU HUE14834828A patent/HUE042081T2/hu unknown
- 2014-08-08 TR TR2018/19812T patent/TR201819812T4/tr unknown
- 2014-08-08 BR BR112016001753-6A patent/BR112016001753B1/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
HUE042081T2 (hu) | 2019-06-28 |
BR112016001753B1 (pt) | 2023-10-03 |
AU2014303375B2 (en) | 2019-07-04 |
JPWO2015020212A1 (ja) | 2017-03-02 |
DK3031826T3 (en) | 2018-12-17 |
EP3031826B1 (en) | 2018-10-10 |
PL3031826T3 (pl) | 2019-03-29 |
PT3031826T (pt) | 2019-01-18 |
MX2016001640A (es) | 2016-06-02 |
EP3031826A4 (en) | 2017-03-29 |
EP3031826A1 (en) | 2016-06-15 |
KR20160038892A (ko) | 2016-04-07 |
RU2678138C2 (ru) | 2019-01-23 |
ES2704909T3 (es) | 2019-03-20 |
CN105452294A (zh) | 2016-03-30 |
JP6447130B2 (ja) | 2019-01-09 |
US20160297889A1 (en) | 2016-10-13 |
WO2015020212A1 (ja) | 2015-02-12 |
MX360671B (es) | 2018-11-13 |
CA2918989C (en) | 2021-11-02 |
US9862774B2 (en) | 2018-01-09 |
AU2014303375A1 (en) | 2016-03-03 |
CN105452294B (zh) | 2019-08-02 |
CA2918989A1 (en) | 2015-02-12 |
TR201819812T4 (tr) | 2019-01-21 |
BR112016001753A2 (pt) | 2017-08-29 |
KR102255616B1 (ko) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016107884A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014108044A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
RU2014108042A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014106671A (ru) | Варианты гуманизированных иммуномодулирующих моноклональных антител | |
HRP20160212T1 (hr) | Antitijela za terapiju kancera koji eksprimira klaudin 6 | |
RU2013152164A (ru) | Анти-в7-н3-антитело | |
MX2015007846A (es) | Anticuerpos anti-b7-h4 humana y sus usos. | |
HRP20171758T1 (hr) | Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene | |
RU2016113757A (ru) | Комбинированная терапия на основе антител против человеческого csf-1r и антител против человеческого pd-l1 | |
RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
RU2012137505A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
RU2020111366A (ru) | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения | |
RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
RU2012137502A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака |